Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

for
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer,
Location: St Louis MO, Rochester MN, Westwood KS
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06374459

Phase 1, Phase 2, Recruiting

Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

for
Solid Tumor
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06563375

Phase 1, Recruiting

Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls

for
Neoplasm
Location: Baltimore MD
Sponsor: Sinai Hospital of Baltimore

Sex: All

Age: 18+

Code: NCT02450175

Recruiting

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

for
Unresectable, Locally Advanced, Metastatic Cancers,
Location: Quebec, Toronto, Cleveland OH, West Valley City UT,
Sponsor: Recursion Pharmaceuticals Inc.

Sex: All

Age: 12+

Code: NCT06678659

Phase 1, Phase 2, Recruiting

Is Radiation-before-pathology a Feasible Approach in the Palliative Oncology Setting? A Pragmatic Clinical Trial

for
Cancer
Location: London
Sponsor: David Palma

Sex: All

Age: 18+

Code: NCT06156800

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

for
Multiple Myeloma, Cancer
Location: Wilmington NC, Durham NC, Chapel Hill NC, Charlotte NC,
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT05145400

Phase 2, Recruiting

Concordance Between Liquid and Tissue Biopsy

for
Breast Neoplasms
Location: London
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Sex: All

Age: 18+

Code: NCT04241237

Recruiting

Cancer Prevention in Women With a BRCA Mutation

for
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Cancer,
Location: Toronto
Sponsor: Women's College Hospital

Sex: Female

Age: 35 - 70

Code: NCT02225015

Phase 1, Recruiting

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

for
Advanced Solid Tumor, Non Small Cell Lung Cancer,
Location: Boston MA, New Haven CT, Lake Success NY, New York NY,
Sponsor: Synthekine

Sex: All

Age: 18+

Code: NCT05098132

Phase 1, Phase 2, Recruiting

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

for
Cancer
Location: Fairhaven MA, Norwich CT, York PA, East Syracuse NY,
Sponsor: Tempus AI

Sex: All

Age: 18 - 70+

Code: NCT06207032

Recruiting

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

for
Advanced Malignant Solid Neoplasm,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05039632

Phase 1, Phase 2, Recruiting

Immune Profiling for Cancer Immunotherapy Response

for
Cancer, Tumor, Solid, Hematologic Malignancy, Blood Cancer
Location: Lebanon NH
Sponsor: Dartmouth-Hitchcock Medical Center

Sex: All

Age: 18+

Code: NCT06116032

Recruiting

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

for
Hormone Receptor-Positive Breast Cancer,
Location: Long Branch NJ, Elizabeth NJ, Newark NJ, Livingston NJ,
Sponsor: Rutgers, The State University of New Jersey

Sex: All

Age: 18+

Code: NCT06518837

Phase 2, Recruiting

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

for
Solid Tumor
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06576037

Phase 1, Recruiting

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

for
HER2-positive Breast Cancer
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT05325632

Phase 2, Recruiting

Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients

for
Hematopoietic and Lymphoid System Neoplasm,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06015932

Recruiting

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

for
Breast Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT05042687

Recruiting

Vincere Biobank Research Protocol

for
Cancer
Location: Scottsdale AZ
Sponsor: Vincere Cancer Center

Sex: All

Age: 18+

Code: NCT05954299

Recruiting

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Duarte CA, Alhambra CA, Pasadena CA, Burbank CA,
Sponsor: Jonsson Comprehensive Cancer Center

Sex: Female

Age: 0+

Code: NCT05595499

Phase 2, Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

for
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Location: Boston MA, Philadelphia PA, Baltimore MD, Columbus OH,
Sponsor: TopAlliance Biosciences

Sex: All

Age: 18+

Code: NCT04137900

Phase 1, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial